169 related articles for article (PubMed ID: 16250930)
1. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
Edelman MJ
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S64-6. PubMed ID: 16250930
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Davies AM; Lara PN; Mack PC; Gumerlock PH; Bold RJ; Gandara DR
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S59-63. PubMed ID: 16250929
[TBL] [Abstract][Full Text] [Related]
3. Sequencing bortezomib with chemotherapy and targeted agents.
Adjei AA
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S56-8. PubMed ID: 16250928
[TBL] [Abstract][Full Text] [Related]
4. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
[TBL] [Abstract][Full Text] [Related]
5. Use of proteasome inhibition in the treatment of lung cancer.
Schenkein DP
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S89-96. PubMed ID: 15638966
[TBL] [Abstract][Full Text] [Related]
6. [Proteasome inhibitors].
Alexandre J
Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
[TBL] [Abstract][Full Text] [Related]
7. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
8. Preclinical data with bortezomib in lung cancer.
Schenkein DP
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S49-55. PubMed ID: 16250927
[TBL] [Abstract][Full Text] [Related]
9. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
Mack PC; Davies AM; Lara PN; Gumerlock PH; Gandara DR
Lung Cancer; 2003 Aug; 41 Suppl 1():S89-96. PubMed ID: 12867067
[TBL] [Abstract][Full Text] [Related]
10. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
Lara PN; Davies AM; Mack PC; Mortenson MM; Bold RJ; Gumerlock PH; Gandara DR
Semin Oncol; 2004 Feb; 31(1 Suppl 1):40-6. PubMed ID: 14981579
[TBL] [Abstract][Full Text] [Related]
12. Activity of bortezomib in advanced non-small-cell lung cancer.
Reddy KG
Clin Lung Cancer; 2004 Nov; 6(3):141-2. PubMed ID: 15555213
[No Abstract] [Full Text] [Related]
13. [Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Soria JC
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S35-6. PubMed ID: 16719155
[No Abstract] [Full Text] [Related]
14. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
[TBL] [Abstract][Full Text] [Related]
15. Incorporating bortezomib into the treatment of lung cancer.
Davies AM; Lara PN; Mack PC; Gandara DR
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4647-51. PubMed ID: 17671158
[TBL] [Abstract][Full Text] [Related]
16. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Neukirchen J; Meier A; Rohrbeck A; Garcia-Pardillos G; Steidl U; Fenk R; Haas R; Kronenwett R; Rohr UP
Cancer Gene Ther; 2007 Apr; 14(4):431-9. PubMed ID: 17235352
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas.
Paoluzzi L; O'Connor OA
BioDrugs; 2006; 20(1):13-23. PubMed ID: 16573348
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors in lung cancer.
Scagliotti G
Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T; López-Corral L; Encinas C; Castilla-Llorente C; Martino R; Rosiñol L; Sampol A; Caballero D; Serrano D; Heras I; San Miguel J; Pérez-Simón JA
Br J Haematol; 2013 Aug; 162(4):474-82. PubMed ID: 23772672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
